ATE554087T1 - Neue kinaseinhibitoren - Google Patents

Neue kinaseinhibitoren

Info

Publication number
ATE554087T1
ATE554087T1 AT05815246T AT05815246T ATE554087T1 AT E554087 T1 ATE554087 T1 AT E554087T1 AT 05815246 T AT05815246 T AT 05815246T AT 05815246 T AT05815246 T AT 05815246T AT E554087 T1 ATE554087 T1 AT E554087T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
compounds
new kinase
methods
new
Prior art date
Application number
AT05815246T
Other languages
English (en)
Inventor
Yujia Dai
Kresna Hartandi
Michael MICHAELIDES
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE554087T1 publication Critical patent/ATE554087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05815246T 2004-10-29 2005-10-28 Neue kinaseinhibitoren ATE554087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62317504P 2004-10-29 2004-10-29
PCT/US2005/038958 WO2006050109A2 (en) 2004-10-29 2005-10-28 Novel kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE554087T1 true ATE554087T1 (de) 2012-05-15

Family

ID=36215668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815246T ATE554087T1 (de) 2004-10-29 2005-10-28 Neue kinaseinhibitoren

Country Status (8)

Country Link
US (1) US7812166B2 (de)
EP (1) EP1807424B1 (de)
JP (1) JP5112875B2 (de)
AT (1) ATE554087T1 (de)
CA (1) CA2585934C (de)
ES (1) ES2386027T3 (de)
MX (1) MX2007005120A (de)
WO (1) WO2006050109A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483283A4 (de) 2002-03-13 2007-04-11 Signum Biosciences Inc Modulation der proteinmethylierung und phosphoproteinphosphat
ES2386027T3 (es) 2004-10-29 2012-08-07 Abbott Laboratories Inhibidores de quinasas novedosos
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1867648A1 (de) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Pyrazolopyridine, ihre Herstellung und ihre medizinische Verwendung
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (de) 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Arylpyrazolopyridine und ihre Salze, diese enthaltende pharmazeutische Zubereitungen, verfahren zu ihrer Herstellung und ihre Verwendung
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1867647A1 (de) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Pyrazolopyridine, ihre Herstellung und ihre medizinische Verwendung
EP1932845A1 (de) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-Pyrazolopyridine und Salze davon, diese enthaltende pharmazeutische Zusammensetzungen , Verfahren zur ihrer Herstellung und ihre Verwendung
KR20090088962A (ko) * 2006-12-15 2009-08-20 바이엘 쉐링 파마 악티엔게젤샤프트 ３-ｈ-피라졸로피리딘 및 그의 염, 이를 포함하는 제약 조성물, 이의 제조 방법 및 이의 용도
EP2042500A1 (de) * 2007-09-21 2009-04-01 Bayer Schering Pharma Aktiengesellschaft N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-Harnstoff-Verbindungen deren pharmazeutische Zusammensetzungen, Verfahren zu deren Herstellung und Verwendungen als Tie2-Kinase Hemmer
WO2009012312A1 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
CA2704266A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
EP2070929A1 (de) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2010129668A1 (en) * 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
CA2764983A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
EP2789615B1 (de) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazole als BTK-Kinasemodulatoren und Verwendung davon
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
CN102869663A (zh) 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并吡嗪激酶抑制剂
CN102985084A (zh) 2010-07-02 2013-03-20 爱尔康研究有限公司 用于治疗眼后节病症和疾病的化合物
US8673922B2 (en) 2010-07-15 2014-03-18 Bristol-Myers Squibb Company Azaindazole compounds
PL2701510T3 (pl) 2011-04-25 2017-07-31 Usher Iii Initiative Inc Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera
CN103214479A (zh) * 2012-01-18 2013-07-24 武汉东宇生物医药科技有限公司 吡唑类萘脲类酪氨酸激酶抑制剂及其应用
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
PL2912038T3 (pl) * 2012-10-25 2019-02-28 Usher Iii Initiative, Inc. Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
CN103524421B (zh) 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
JP6912016B1 (ja) * 2020-04-10 2021-07-28 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
IL299695A (en) 2020-07-09 2023-03-01 Usher Iii Initiative Inc Treatment of cancer, inflammatory diseases and autoimmune diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT990809B (it) * 1972-06-30 1975-07-10 Hoechst Ag Coloranti azoici basici procedi mento per la loro preparazione e e loro impiego
DE2238400A1 (de) * 1972-08-04 1974-02-14 Hoechst Ag Basische azofarbstoffe, verfahren zu ihrer herstellung und ihre verwendung
DE2643753A1 (de) * 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ES2299434T3 (es) * 1999-09-17 2008-06-01 ABBOTT GMBH & CO. KG Inhibidores de kinasa utilizados como agentes terapeuticos.
DE60232669D1 (de) * 2001-04-30 2009-07-30 Vertex Pharma Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
ES2386027T3 (es) 2004-10-29 2012-08-07 Abbott Laboratories Inhibidores de quinasas novedosos

Also Published As

Publication number Publication date
WO2006050109A3 (en) 2006-08-03
EP1807424B1 (de) 2012-04-18
ES2386027T3 (es) 2012-08-07
JP2008518928A (ja) 2008-06-05
CA2585934A1 (en) 2006-05-11
EP1807424A2 (de) 2007-07-18
CA2585934C (en) 2013-09-10
MX2007005120A (es) 2007-07-16
US20060178378A1 (en) 2006-08-10
WO2006050109A2 (en) 2006-05-11
US7812166B2 (en) 2010-10-12
JP5112875B2 (ja) 2013-01-09

Similar Documents

Publication Publication Date Title
ATE554087T1 (de) Neue kinaseinhibitoren
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
DK1638941T3 (da) Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
TW200801008A (en) Protein kinase inhibitors
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA201000093A1 (ru) Производные пиридазинона
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
EA200901601A1 (ru) Производные пиридазинона
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
DK1761520T3 (da) Kinaseinhibitorer
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
UA85505C2 (en) Kinase inhibitors
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
EA200800010A1 (ru) Промежуточные соединения, используемые в синтезе алкилхинолиновых и алкилхиназолиновых модуляторов киназ, и соответствующие способы синтеза